{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:36:49Z","timestamp":1780436209968,"version":"3.54.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,27]]},"DOI":"10.7759\/cureus.91103","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:26:24Z","timestamp":1756301184000},"source":"Crossref","is-referenced-by-count":1,"title":["Nanoparticles as Drug Delivery Systems in Intravesical Therapy for Non-muscle Invasive Bladder Cancer: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Jan","family":"G\u00f3rski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Ziembicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Pierudzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Global cancer observatory: cancer today","author":"Ferlay J","year":"2024","unstructured":"Ferlay J, Ervik M, Lam F, et al.. Global cancer observatory: cancer today. International Agency for Research on Cancer (IARC). International Agency for Research on Cancer, Lyon, France; 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay J","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021, 149:778-89. 10.1002\/ijc.33588","journal-title":"Int J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel RL","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020, 70:7-30. 10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective","volume":"19","author":"Teoh JY","year":"2022","unstructured":"Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol. 2022, 19:280-94. 10.1038\/s41585-022-00578-1","journal-title":"Nat Rev Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10027","article-title":"Significance of 5-aminolevulinic acid-mediated photodynamic diagnosis following standard transurethral resection in non-muscle invasive bladder cancer","volume":"1","author":"Watanabe K","year":"2021","unstructured":"Watanabe K, Tamura K, Matsushita Y, et al.. Significance of 5-aminolevulinic acid-mediated photodynamic diagnosis following standard transurethral resection in non-muscle invasive bladder cancer. Cancer Diagn Progn. 2021, 1:201-5. 10.21873\/cdp.10027","journal-title":"Cancer Diagn Progn"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122724","article-title":"Local drug delivery in bladder cancer: advances of nano\/micro\/macro-scale drug delivery systems","volume":"15","author":"Marchenko IV","year":"2023","unstructured":"Marchenko IV, Trushina DB. Local drug delivery in bladder cancer: advances of nano\/micro\/macro-scale drug delivery systems. Pharmaceutics. 2023, 15:2724. 10.3390\/pharmaceutics15122724","journal-title":"Pharmaceutics"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114062","article-title":"Current advances in the application of nanomedicine in bladder cancer","volume":"157","author":"Zhang C","year":"2023","unstructured":"Zhang C, Zhao J, Wang W, Geng H, Wang Y, Gao B. Current advances in the application of nanomedicine in bladder cancer. Biomed Pharmacother. 2023, 157:114062. 10.1016\/j.biopha.2022.114062","journal-title":"Biomed Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3762\/bjnano.9.98","article-title":"Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations","volume":"9","author":"Jeevanandam J","year":"2018","unstructured":"Jeevanandam J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol. 2018, 9:1050-74. 10.3762\/bjnano.9.98","journal-title":"Beilstein J Nanotechnol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5644\/ama2006-124.332","article-title":"New insights into the diagnosis, molecular taxonomy, and treatment of bladder cancer","volume":"50","author":"Ulamec M","year":"2021","unstructured":"Ulamec M, Murgi\u0107 J, Novosel L, et al.. New insights into the diagnosis, molecular taxonomy, and treatment of bladder cancer. Acta Med Acad. 2021, 50:143-56. 10.5644\/ama2006-124.332","journal-title":"Acta Med Acad"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester RJ","year":"2021","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V, et al.. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021, 79:480-8. 10.1016\/j.eururo.2020.12.033","journal-title":"Eur Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2310073","article-title":"Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?","volume":"25","author":"Abou Chakra M","year":"2024","unstructured":"Abou Chakra M, Packiam VT, Duquesne I, Peyromaure M, McElree IM, O'Donnell MA. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?. Expert Opin Pharmacother. 2024, 25:203-14. 10.1080\/14656566.2024.2310073","journal-title":"Expert Opin Pharmacother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.05.050","article-title":"Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?","volume":"69","author":"Sylvester RJ","year":"2016","unstructured":"Sylvester RJ, Oosterlinck W, Holmang S, et al.. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?. Eur Urol. 2016, 69:231-44. 10.1016\/j.eururo.2015.05.050","journal-title":"Eur Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj GV","year":"2007","unstructured":"Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol. 2007, 177:1283-6. 10.1016\/j.juro.2006.11.090","journal-title":"J Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - a summary of the 2024 guidelines update","volume":"86","author":"Gontero P","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O, et al.. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - a summary of the 2024 guidelines update. Eur Urol. 2024, 86:531-49. 10.1016\/j.eururo.2024.07.027","journal-title":"Eur Urol"},{"key":"ref16","article-title":"Carcinoma in situ","volume":"19","author":"Lamm DL","year":"1992","unstructured":"Lamm DL. Carcinoma in situ. Urol Clin North Am. 1992, 19:499-508.","journal-title":"Urol Clin North Am"},{"key":"ref17","article-title":"Principles of Anatomy and Physiology","author":"Tortora GJ","year":"2016","unstructured":"Tortora GJ, Derrickson BH. Principles of Anatomy and Physiology. Guarascio M (ed): John Wiley & Sons, Hoboken, NJ; 2016."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1021\/mp060001j","article-title":"Recent advances in intravesical drug\/gene delivery","volume":"3","author":"Tyagi P","year":"2006","unstructured":"Tyagi P, Wu PC, Chancellor M, Yoshimura N, Huang L. Recent advances in intravesical drug\/gene delivery. Mol Pharm. 2006, 3:369-79. 10.1021\/mp060001j","journal-title":"Mol Pharm"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.2000.278.6.F867","article-title":"Everything you wanted to know about the bladder epithelium but were afraid to ask","volume":"278","author":"Lewis SA","year":"2000","unstructured":"Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol. 2000, 278:F867-74. 10.1152\/ajprenal.2000.278.6.F867","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)36889-8","article-title":"Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins","volume":"269","author":"Wu XR","year":"1994","unstructured":"Wu XR, Lin JH, Walz T, H\u00e4ner M, Yu J, Aebi U, Sun TT. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem. 1994, 269:13716-24. 10.1016\/S0021-9258(17)36889-8","journal-title":"J Biol Chem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010211","article-title":"The progress of chitosan-based nanoparticles for intravesical bladder cancer treatment","volume":"15","author":"Yu C","year":"2023","unstructured":"Yu C, Wang S, Lai WF, Zhang D. The progress of chitosan-based nanoparticles for intravesical bladder cancer treatment. Pharmaceutics. 2023, 15:211. 10.3390\/pharmaceutics15010211","journal-title":"Pharmaceutics"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.08.031","article-title":"Intravesical drug delivery: challenges, current status, opportunities and novel strategies","volume":"148","author":"GuhaSarkar S","year":"2010","unstructured":"GuhaSarkar S, Banerjee R. Intravesical drug delivery: challenges, current status, opportunities and novel strategies. J Control Release. 2010, 148:147-59. 10.1016\/j.jconrel.2010.08.031","journal-title":"J Control Release"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092214","article-title":"Nanotechnology in bladder cancer: diagnosis and treatment","volume":"13","author":"Barani M","year":"2021","unstructured":"Barani M, Hosseinikhah SM, Rahdar A, Farhoudi L, Arshad R, Cucchiarini M, Pandey S. Nanotechnology in bladder cancer: diagnosis and treatment. Cancers (Basel). 2021, 13:2214. 10.3390\/cancers13092214","journal-title":"Cancers (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11051-020-05129-6","article-title":"Nanodiagnosis and nanotreatment of colorectal cancer: an overview","volume":"23","author":"Barani M","year":"2021","unstructured":"Barani M, Bilal M, Rahdar A, Arshad R, Kumar A, Hamishekar H, Kyzas GZ. Nanodiagnosis and nanotreatment of colorectal cancer: an overview. J Nanoparticle Res. 2021, 23:18. 10.1007\/s11051-020-05129-6","journal-title":"J Nanoparticle Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202004172","article-title":"Active transportation of liposome enhances tumor accumulation, penetration, and therapeutic efficacy","volume":"16","author":"Wang G","year":"2020","unstructured":"Wang G, Wu B, Li Q, et al.. Active transportation of liposome enhances tumor accumulation, penetration, and therapeutic efficacy. Small. 2020, 16:e2004172. 10.1002\/smll.202004172","journal-title":"Small"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126547","article-title":"Basic methods for preparation of liposomes and studying their interactions with different compounds, with the emphasis on polyphenols","volume":"22","author":"\u0160turm L","year":"2021","unstructured":"\u0160turm L, Poklar Ulrih N. Basic methods for preparation of liposomes and studying their interactions with different compounds, with the emphasis on polyphenols. Int J Mol Sci. 2021, 22:6547. 10.3390\/ijms22126547","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.025","article-title":"Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy","volume":"69","author":"Moosavian SA","year":"2021","unstructured":"Moosavian SA, Bianconi V, Pirro M, Sahebkar A. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. Semin Cancer Biol. 2021, 69:337-48. 10.1016\/j.semcancer.2019.09.025","journal-title":"Semin Cancer Biol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.01.007","article-title":"Composition design and medical application of liposomes","volume":"164","author":"Li M","year":"2019","unstructured":"Li M, Du C, Guo N, et al.. Composition design and medical application of liposomes. Eur J Med Chem. 2019, 164:640-53. 10.1016\/j.ejmech.2019.01.007","journal-title":"Eur J Med Chem"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123679","article-title":"Liposome-encapsulated Bacillus Calmette-Gu\u00e9rin cell wall skeleton enhances antitumor efficiency for bladder cancer in vitro and in vivo via induction of AMP-activated protein kinase","volume":"12","author":"Whang YM","year":"2020","unstructured":"Whang YM, Yoon DH, Hwang GY, Yoon H, Park SI, Choi YW, Chang IH. Liposome-encapsulated Bacillus Calmette-Gu\u00e9rin cell wall skeleton enhances antitumor efficiency for bladder cancer in vitro and in vivo via induction of AMP-activated protein kinase. Cancers (Basel). 2020, 12:3679. 10.3390\/cancers12123679","journal-title":"Cancers (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000952.01","article-title":"MP72-01 phase 1 outcomes of a novel third-generation liposomal paclitaxel formulation (TSD-001) in low-intermediate risk non-muscle-invasive bladder cancer (NMIBC) patients","volume":"203","author":"Oefelein M","year":"2020","unstructured":"Oefelein M, Danny H, Rian D, Karl B. MP72-01 phase 1 outcomes of a novel third-generation liposomal paclitaxel formulation (TSD-001) in low-intermediate risk non-muscle-invasive bladder cancer (NMIBC) patients. J Urol. 2020, 203:1073. 10.1097\/JU.0000000000000952.01","journal-title":"J Urol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225776","article-title":"Synthesis, bioapplications, and toxicity evaluation of chitosan-based nanoparticles","volume":"20","author":"Rizeq BR","year":"2019","unstructured":"Rizeq BR, Younes NN, Rasool K, Nasrallah GK. Synthesis, bioapplications, and toxicity evaluation of chitosan-based nanoparticles. Int J Mol Sci. 2019, 20:5776. 10.3390\/ijms20225776","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.8b00501","article-title":"Paclitaxel\/chitosan nanosuspensions provide enhanced intravesical bladder cancer therapy with sustained and prolonged delivery of paclitaxel","volume":"1","author":"Liu Y","year":"2018","unstructured":"Liu Y, Wang R, Hou J, et al.. Paclitaxel\/chitosan nanosuspensions provide enhanced intravesical bladder cancer therapy with sustained and prolonged delivery of paclitaxel. ACS Appl Bio Mater. 2018, 1:1992-2001. 10.1021\/acsabm.8b00501","journal-title":"ACS Appl Bio Mater"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4644(1997)27+%3C42::AID-JCB9%3E3.0.CO;2-1","article-title":"Chemopreventive properties of indole-3-carbinol (I3C): inhibition of DNA adduct formation of the dietary carcinogen, 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP), in female F344 rats","volume":"27","author":"He YH","year":"1997","unstructured":"He YH, Smale MH, Schut HA. Chemopreventive properties of indole-3-carbinol (I3C): inhibition of DNA adduct formation of the dietary carcinogen, 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP), in female F344 rats. J Cell Biochem. 1997, 27:42-51. 10.1002\/(SICI)1097-4644(1997)27+%3C42::AID-JCB9%3E3.0.CO;2-1","journal-title":"J Cell Biochem"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2021.112089","article-title":"Chitosan and chitosan\/PEG nanoparticles loaded with indole-3-carbinol: characterization, computational study and potential effect on human bladder cancer cells","volume":"124","author":"Melo MN","year":"2021","unstructured":"Melo MN, Pereira FM, Rocha MA, et al.. Chitosan and chitosan\/PEG nanoparticles loaded with indole-3-carbinol: characterization, computational study and potential effect on human bladder cancer cells. Mater Sci Eng C Mater Biol Appl. 2021, 124:112089. 10.1016\/j.msec.2021.112089","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S277645","article-title":"Gambogic acid as a candidate for cancer therapy: a review","volume":"15","author":"Liu Y","year":"2020","unstructured":"Liu Y, Chen Y, Lin L, Li H. Gambogic acid as a candidate for cancer therapy: a review. Int J Nanomedicine. 2020, 15:10385-99. 10.2147\/IJN.S277645","journal-title":"Int J Nanomedicine"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.03.028","article-title":"Mucoadhesive nanoparticles based on ROS activated gambogic acid prodrug for safe and efficient intravesical instillation chemotherapy of bladder cancer","volume":"324","author":"Xu X","year":"2020","unstructured":"Xu X, Liu K, Jiao B, et al.. Mucoadhesive nanoparticles based on ROS activated gambogic acid prodrug for safe and efficient intravesical instillation chemotherapy of bladder cancer. J Control Release. 2020, 324:493-504. 10.1016\/j.jconrel.2020.03.028","journal-title":"J Control Release"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/nano10091657","article-title":"Microemulsion microstructure(s): a tutorial review","volume":"10","author":"Tartaro G","year":"2020","unstructured":"Tartaro G, Mateos H, Schirone D, Angelico R, Palazzo G. Microemulsion microstructure(s): a tutorial review. Nanomaterials (Basel). 2020, 10:1657. 10.3390\/nano10091657","journal-title":"Nanomaterials (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fnano.2021.754889","article-title":"Microemulsions: unique properties, pharmacological applications, and targeted drug delivery","volume":"3","author":"Suhail N","year":"2021","unstructured":"Suhail N, Alzahrani AK, Basha WJ, Kizilbash N, Zaidi A, Ambreen J, Khachfe HM. Microemulsions: unique properties, pharmacological applications, and targeted drug delivery. Front Nanotechnol. 2021, 3:754889. 10.3389\/fnano.2021.754889","journal-title":"Front Nanotechnol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2018.06.006","article-title":"Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: experience over the last decade","volume":"6","author":"Goel S","year":"2019","unstructured":"Goel S, Sinha RJ, Bhaskar V, Aeron R, Sharma A, Singh V. Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: experience over the last decade. Asian J Urol. 2019, 6:222-9. 10.1016\/j.ajur.2018.06.006","journal-title":"Asian J Urol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12100949","article-title":"Co-delivery of cisplatin and gemcitabine via viscous nanoemulsion for potential synergistic intravesical chemotherapy","volume":"12","author":"Chen TY","year":"2020","unstructured":"Chen TY, Tsai MJ, Chang LC, Wu PC. Co-delivery of cisplatin and gemcitabine via viscous nanoemulsion for potential synergistic intravesical chemotherapy. Pharmaceutics. 2020, 12:949. 10.3390\/pharmaceutics12100949","journal-title":"Pharmaceutics"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10070238","article-title":"Micelles structure development as a strategy to improve smart cancer therapy","volume":"10","author":"Hanafy NA","year":"2018","unstructured":"Hanafy NA, El-Kemary M, Leporatti S. Micelles structure development as a strategy to improve smart cancer therapy. Cancers (Basel). 2018, 10:238. 10.3390\/cancers10070238","journal-title":"Cancers (Basel)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.02.031","article-title":"Polymeric micelles in drug delivery: an insight of the techniques for their characterization and assessment in biorelevant conditions","volume":"332","author":"Ghezzi M","year":"2021","unstructured":"Ghezzi M, Pescina S, Padula C, Santi P, Del Favero E, Cant\u00f9 L, Nicoli S. Polymeric micelles in drug delivery: an insight of the techniques for their characterization and assessment in biorelevant conditions. J Control Release. 2021, 332:312-36. 10.1016\/j.jconrel.2021.02.031","journal-title":"J Control Release"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08132.x","article-title":"Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy","volume":"103","author":"Mugabe C","year":"2009","unstructured":"Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, Burt HM. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int. 2009, 103:978-86. 10.1111\/j.1464-410X.2008.08132.x","journal-title":"BJU Int"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1021\/bm300966d","article-title":"Biodegradable hyperbranched polyglycerol with ester linkages for drug delivery","volume":"13","author":"Hu M","year":"2012","unstructured":"Hu M, Chen M, Li G, et al.. Biodegradable hyperbranched polyglycerol with ester linkages for drug delivery. Biomacromolecules. 2012, 13:3552-61. 10.1021\/bm300966d","journal-title":"Biomacromolecules"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2008.09.023","article-title":"Dendrimers as versatile platform in drug delivery applications","volume":"71","author":"Svenson S","year":"2009","unstructured":"Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm. 2009, 71:445-62. 10.1016\/j.ejpb.2008.09.023","journal-title":"Eur J Pharm Biopharm"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2005.09.019","article-title":"Dendrimer biocompatibility and toxicity","volume":"57","author":"Duncan R","year":"2005","unstructured":"Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 2005, 57:2215-37. 10.1016\/j.addr.2005.09.019","journal-title":"Adv Drug Deliv Rev"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-1723(03)80059-2","article-title":"Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine dendrimer","volume":"95","author":"Wang Z","year":"2003","unstructured":"Wang Z, Itoh Y, Hosaka Y, et al.. Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine dendrimer. J Biosci Bioeng. 2003, 95:541-3. 10.1016\/S1389-1723(03)80059-2","journal-title":"J Biosci Bioeng"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S140111","article-title":"Drug delivery system based on dendritic nanoparticles for enhancement of intravesical instillation","volume":"12","author":"Qiu X","year":"2017","unstructured":"Qiu X, Cao K, Lin T, et al.. Drug delivery system based on dendritic nanoparticles for enhancement of intravesical instillation. Int J Nanomedicine. 2017, 12:7365-74. 10.2147\/IJN.S140111","journal-title":"Int J Nanomedicine"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2017.1400553","article-title":"Recent advances in metal nanoparticles in cancer therapy","volume":"26","author":"Sharma A","year":"2018","unstructured":"Sharma A, Goyal AK, Rath G. Recent advances in metal nanoparticles in cancer therapy. J Drug Target. 2018, 26:617-32. 10.1080\/1061186X.2017.1400553","journal-title":"J Drug Target"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1912008","article-title":"Metallic nanoparticles as drug delivery system for the treatment of cancer","volume":"18","author":"Neha D","year":"2021","unstructured":"Neha D, Momin M, Khan T, Gharat S, Ningthoujam RS, Omri A. Metallic nanoparticles as drug delivery system for the treatment of cancer. Expert Opin Drug Deliv. 2021, 18:1261-90. 10.1080\/17425247.2021.1912008","journal-title":"Expert Opin Drug Deliv"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/528123","article-title":"Nanoparticles for targeted delivery of active agents against tumor cells","volume":"2012","author":"Dinarvand R","year":"2012","unstructured":"Dinarvand R, Cesar de Morais P, D'Emanuele A. Nanoparticles for targeted delivery of active agents against tumor cells. J Drug Deliv. 2012, 2012:528123. 10.1155\/2012\/528123","journal-title":"J Drug Deliv"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02559-y","article-title":"Rapid noninvasive detection of bladder cancer using survivin antibody-conjugated gold nanoparticles (GNPs) based on localized surface plasmon resonance (LSPR)","volume":"69","author":"Jazayeri MH","year":"2020","unstructured":"Jazayeri MH, Aghaie T, Nedaeinia R, Manian M, Nickho H. Rapid noninvasive detection of bladder cancer using survivin antibody-conjugated gold nanoparticles (GNPs) based on localized surface plasmon resonance (LSPR). Cancer Immunol Immunother. 2020, 69:1833-40. 10.1007\/s00262-020-02559-y","journal-title":"Cancer Immunol Immunother"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19071979","article-title":"Gold nanoparticles in diagnostics and therapeutics for human cancer","volume":"19","author":"Singh P","year":"2018","unstructured":"Singh P, Pandit S, Mokkapati VR, Garg A, Ravikumar V, Mijakovic I. Gold nanoparticles in diagnostics and therapeutics for human cancer. Int J Mol Sci. 2018, 19:1979. 10.3390\/ijms19071979","journal-title":"Int J Mol Sci"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.sciaf.2020.e00685","article-title":"Gold nanoparticles as a drug delivery system for standard chemotherapeutics: a new lead for targeted pharmacological cancer treatments","volume":"11","author":"Yafout M","year":"2021","unstructured":"Yafout M, Ousaid A, Khayati Y, El Otmani IS. Gold nanoparticles as a drug delivery system for standard chemotherapeutics: a new lead for targeted pharmacological cancer treatments. Scientific African. 2021, 11:e00685. 10.1016\/j.sciaf.2020.e00685","journal-title":"Scientific African"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.04.012","article-title":"Biogenic silver nanoparticles: in vitro and in vivo antitumor activity in bladder cancer","volume":"151","author":"Ferreira LA","year":"2020","unstructured":"Ferreira LA, Garcia-Fossa F, Radaic A, Dur\u00e1n N, F\u00e1varo WJ, de Jesus MB. Biogenic silver nanoparticles: in vitro and in vivo antitumor activity in bladder cancer. Eur J Pharm Biopharm. 2020, 151:162-70. 10.1016\/j.ejpb.2020.04.012","journal-title":"Eur J Pharm Biopharm"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.112254","article-title":"Exploring silver nanoparticles for cancer therapy and diagnosis","volume":"210","author":"Miranda RR","year":"2022","unstructured":"Miranda RR, Sampaio I, Zucolotto V. Exploring silver nanoparticles for cancer therapy and diagnosis. Colloids Surf B Biointerfaces. 2022, 210:112254. 10.1016\/j.colsurfb.2021.112254","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3109\/21691401.2016.1153483","article-title":"Magnetic nanoparticles in cancer diagnosis and treatment: a review","volume":"45","author":"Fathi Karkan S","year":"2017","unstructured":"Fathi Karkan S, Mohammadhosseini M, Panahi Y, et al.. Magnetic nanoparticles in cancer diagnosis and treatment: a review. Artif Cells Nanomed Biotechnol. 2017, 45:1-5. 10.3109\/21691401.2016.1153483","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101535","article-title":"Targeted drug delivery systems for bladder cancer therapy","volume":"56","author":"Yu K","year":"2020","unstructured":"Yu K, Liu M, Dai H, Huang X. Targeted drug delivery systems for bladder cancer therapy. J Drug Deliv Sci Technol. 2020, 56:101535. 10.1016\/j.jddst.2020.101535","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1002\/asia.201500232","article-title":"Prussian blue-derived nanoporous iron oxides as anticancer drug carriers for magnetic-guided chemotherapy","volume":"10","author":"Zakaria MB","year":"2015","unstructured":"Zakaria MB, Belik AA, Liu CH, et al.. Prussian blue-derived nanoporous iron oxides as anticancer drug carriers for magnetic-guided chemotherapy. Chem Asian J. 2015, 10:1457-62. 10.1002\/asia.201500232","journal-title":"Chem Asian J"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2016.2271","article-title":"Aptamer-directed specific drug delivery and magnetic resonance imaging of renal carcinoma cells in vitro and in vivo","volume":"12","author":"Li J","year":"2016","unstructured":"Li J, Wang J, Sun D, et al.. Aptamer-directed specific drug delivery and magnetic resonance imaging of renal carcinoma cells in vitro and in vivo. J Biomed Nanotechnol. 2016, 12:1604-16. 10.1166\/jbn.2016.2271","journal-title":"J Biomed Nanotechnol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201902634","article-title":"Mesoporous silica nanoparticles for drug delivery","volume":"30","author":"Manzano M","year":"2020","unstructured":"Manzano M, Vallet-Reg\u00ed M. Mesoporous silica nanoparticles for drug delivery. Adv Funct Mater. 2020, 30:1902634. 10.1002\/adfm.201902634","journal-title":"Adv Funct Mater"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201500437","article-title":"Lanthanide-doped upconversion nanoparticles: emerging intelligent light-activated drug delivery systems","volume":"3","author":"Bagheri A","year":"2016","unstructured":"Bagheri A, Arandiyan H, Boyer C, Lim M. Lanthanide-doped upconversion nanoparticles: emerging intelligent light-activated drug delivery systems. Adv Sci (Weinh). 2016, 3:1500437. 10.1002\/advs.201500437","journal-title":"Adv Sci (Weinh)"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2010.09.069","article-title":"Drug delivery with upconversion nanoparticles for multi-functional targeted cancer cell imaging and therapy","volume":"32","author":"Wang C","year":"2011","unstructured":"Wang C, Cheng L, Liu Z. Drug delivery with upconversion nanoparticles for multi-functional targeted cancer cell imaging and therapy. Biomaterials. 2011, 32:1110-20. 10.1016\/j.biomaterials.2010.09.069","journal-title":"Biomaterials"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23020378","article-title":"Cancer targeting and drug delivery using carbon-based quantum dots and nanotubes","volume":"23","author":"Pardo J","year":"2018","unstructured":"Pardo J, Peng Z, Leblanc RM. Cancer targeting and drug delivery using carbon-based quantum dots and nanotubes. Molecules. 2018, 23:378. 10.3390\/molecules23020378","journal-title":"Molecules"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/ma14205978","article-title":"Biomedical applications of carbon nanomaterials: fullerenes, quantum dots, nanotubes, nanofibers, and graphene","volume":"14","author":"Gaur M","year":"2021","unstructured":"Gaur M, Misra C, Yadav AB, Swaroop S, Maolmhuaidh F\u00d3, Bechelany M, Barhoum A. Biomedical applications of carbon nanomaterials: fullerenes, quantum dots, nanotubes, nanofibers, and graphene. Materials (Basel). 2021, 14:5978. 10.3390\/ma14205978","journal-title":"Materials (Basel)"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091512","article-title":"Graphene oxide and graphene quantum dots as delivery systems of cationic porphyrins: photo-antiproliferative activity evaluation towards T24 human bladder cancer cells","volume":"13","author":"Menilli L","year":"2021","unstructured":"Menilli L, Monteiro AR, Lazzarotto S, et al.. Graphene oxide and graphene quantum dots as delivery systems of cationic porphyrins: photo-antiproliferative activity evaluation towards T24 human bladder cancer cells. Pharmaceutics. 2021, 13:1512. 10.3390\/pharmaceutics13091512","journal-title":"Pharmaceutics"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1590\/s0100-879x2012007500111","article-title":"In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer","volume":"45","author":"Chen G","year":"2012","unstructured":"Chen G, He Y, Wu X, Zhang Y, Luo C, Jing P. In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer. Braz J Med Biol Res. 2012, 45:771-6. 10.1590\/s0100-879x2012007500111","journal-title":"Braz J Med Biol Res"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1177\/0748233717747472","article-title":"Toxicity of carbon nanotubes: a review","volume":"34","author":"Francis AP","year":"2018","unstructured":"Francis AP, Devasena T. Toxicity of carbon nanotubes: a review. Toxicol Ind Health. 2018, 34:200-10. 10.1177\/0748233717747472","journal-title":"Toxicol Ind Health"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-27758-0_243-3","article-title":"Composite nanoparticles","author":"Luo G","year":"2014","unstructured":"Luo G, Du L, Wang Y, Wang K. Composite nanoparticles. Encyclopedia of Microfluidics and Nanofluidics. Li D (ed): Springer, Boston, MA; 2014. 10.1007\/978-3-642-27758-0_243-3"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.958072","article-title":"Improvement of the bladder perfusion curative effect through tight junction protein degradation induced by magnetic temperature-sensitive hydrogels","volume":"10","author":"Sun X","year":"2022","unstructured":"Sun X, Song X, Guo P, et al.. Improvement of the bladder perfusion curative effect through tight junction protein degradation induced by magnetic temperature-sensitive hydrogels. Front Bioeng Biotechnol. 2022, 10:958072. 10.3389\/fbioe.2022.958072","journal-title":"Front Bioeng Biotechnol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S189688","article-title":"Magnetic multiwalled carbon nanotubes with controlled release of epirubicin: an intravesical instillation system for bladder cancer","volume":"14","author":"Suo N","year":"2019","unstructured":"Suo N, Wang M, Jin Y, et al.. Magnetic multiwalled carbon nanotubes with controlled release of epirubicin: an intravesical instillation system for bladder cancer. Int J Nanomedicine. 2019, 14:1241-54. 10.2147\/IJN.S189688","journal-title":"Int J Nanomedicine"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/387415-nanoparticles-as-drug-delivery-systems-in-intravesical-therapy-for-non-muscle-invasive-bladder-cancer-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:26:25Z","timestamp":1756301185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/387415-nanoparticles-as-drug-delivery-systems-in-intravesical-therapy-for-non-muscle-invasive-bladder-cancer-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":71,"URL":"https:\/\/doi.org\/10.7759\/cureus.91103","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}